Cisco Stock Forecast: Is It Ready to Surprise Us?
Let’s be real Cisco Systems (NASDAQ: CSCO) hasn’t exactly been…
Sell
31
DVAX Quote, Financials, Valuation and Earnings
Last price:
$9.80
Seasonality move
:
12%
Day range:
$9.61 - $9.84
52-week range:
$9.22 - $14.63
Dividend yield:
0%
P/E ratio:
54.00x
P/S ratio:
4.71x
P/B ratio:
2.22x
Volume:
1.3M
Avg. volume:
2.4M
1-year change:
-17.3%
Market cap:
$1.2B
Revenue:
$277.2M
EPS (TTM):
-$0.52
Analysts' Opinion
-
Consensus RatingDynavax Technologies has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.28, Dynavax Technologies has an estimated upside of 137.5% from its current price of $9.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.10 representing 100% downside risk from its current price of $9.80.
Fair Value
-
According to the consensus of 2 analysts, Dynavax Technologies has 137.5% upside to fair value with a price target of $23.28 per share.
DVAX vs. S&P 500
-
Over the past 5 trading days, Dynavax Technologies has overperformed the S&P 500 by 4.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Dynavax Technologies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dynavax Technologies has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Dynavax Technologies reported revenues of $68.2M.
Earnings Growth
-
Dynavax Technologies has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Dynavax Technologies reported earnings per share of -$0.77.
Enterprise value:
776M
EV / Invested capital:
--
Price / LTM sales:
4.71x
EV / EBIT:
19.02x
EV / Revenue:
2.63x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.36x
Price / Operating cash flow:
25.70x
Enterprise value / EBITDA:
15.67x
Gross Profit (TTM):
$242.4M
Return On Assets:
-6.01%
Net Income Margin (TTM):
-20.39%
Return On Equity:
-9.78%
Return On Invested Capital:
-7.11%
Operating Margin:
-18.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $655.6M | $236.1M | $294.6M | $50.8M | $68.2M | |
| Gross Profit | $418.7M | $189.7M | $242.4M | $39.8M | $54.4M | |
| Operating Income | $233.8M | -$25.5M | $988K | -$17.8M | -$12.7M | |
| EBITDA | $251M | $22.2M | -$40.6M | -$8.1M | -$94.4M | |
| Diluted EPS | $1.56 | $0.06 | -$0.52 | -$0.07 | -$0.77 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $427.5M | $940.5M | $830.1M | $851.3M | $816M | |
| Total Assets | $490.1M | $1B | $969.9M | $986.6M | $945.9M | |
| Current Liabilities | $109.4M | $466.2M | $91.5M | $56M | $68.4M | |
| Total Liabilities | $390.4M | $721.5M | $406.2M | $368.1M | $415M | |
| Total Equity | $99.8M | $287.5M | $563.7M | $618.5M | $530.9M | |
| Total Debt | $179.9M | $220.8M | $221.9M | $223M | $260.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $140.8M | $56.3M | $63.6M | -$16.7M | -$19.6M | |
| Cash From Investing | -$151.8M | -$98.8M | -$14M | $2.8M | $6.9M | |
| Cash From Financing | $6.1M | $273K | -$129.7M | -$4.2M | -$31.9M | |
| Free Cash Flow | $133.7M | $52.7M | $54M | -$17.4M | -$23.6M | |
DVAX
Sector
Market Cap
$1.2B
$34.8M
Price % of 52-Week High
66.99%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-17.3%
-41.1%
Beta (5-Year)
1.261
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.79
200-day SMA
Sell
Level
$11.98
Bollinger Bands (100)
Sell
Level
10.96 - 13.66
Chaikin Money Flow
Sell
Level
-8M
20-day SMA
Sell
Level
$10.31
Relative Strength Index (RSI14)
Sell
Level
40.15
ADX Line
Sell
Level
33.71
Williams %R
Neutral
Level
-70.8543
50-day SMA
Sell
Level
$11.55
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-15M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5302)
Buy
CA Score
(Annual)
Level (0.3412)
Buy
Beneish M-Score
(Annual)
Level (-2.5958)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.9658)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Stock Forecast FAQ
In the current month, DVAX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DVAX average analyst price target in the past 3 months is $23.28.
-
Where Will Dynavax Technologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dynavax Technologies share price will rise to $23.28 per share over the next 12 months.
-
What Do Analysts Say About Dynavax Technologies?
Analysts are divided on their view about Dynavax Technologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dynavax Technologies is a Sell and believe this share price will drop from its current level to $11.10.
-
What Is Dynavax Technologies's Price Target?
The price target for Dynavax Technologies over the next 1-year time period is forecast to be $23.28 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DVAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dynavax Technologies is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DVAX?
You can purchase shares of Dynavax Technologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dynavax Technologies shares.
-
What Is The Dynavax Technologies Share Price Today?
Dynavax Technologies was last trading at $9.80 per share. This represents the most recent stock quote for Dynavax Technologies. Yesterday, Dynavax Technologies closed at $9.80 per share.
-
How To Buy Dynavax Technologies Stock Online?
In order to purchase Dynavax Technologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Gartner Stock Be in 5 Years?
If you’ve ever wondered what it’s like to invest in…
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus has flown under the radar, but the numbers tell…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
